439 related articles for article (PubMed ID: 28721490)
1. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
2. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
[TBL] [Abstract][Full Text] [Related]
3. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
[TBL] [Abstract][Full Text] [Related]
4. Invasive micropapillary urothelial carcinoma of the bladder.
Lopez-Beltran A; Montironi R; Blanca A; Cheng L
Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of prominent retraction clefts in invasive urothelial carcinoma.
Shah TS; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff DJ; Chen G; Warrick JI
Hum Pathol; 2017 Mar; 61():90-96. PubMed ID: 27818288
[TBL] [Abstract][Full Text] [Related]
6. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
[TBL] [Abstract][Full Text] [Related]
7. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.
Reddy OL; Cates JM; Gellert LL; Crist HS; Yang Z; Yamashita H; Taylor JA; Smith JA; Chang SS; Cookson MS; You C; Barocas DA; Grabowska MM; Ye F; Wu XR; Yi Y; Matusik RJ; Kaestner KH; Clark PE; DeGraff DJ
Am J Pathol; 2015 May; 185(5):1385-95. PubMed ID: 25907831
[TBL] [Abstract][Full Text] [Related]
8. Transition between urothelial carcinoma in situ and non-invasive micropapillary carcinoma as a pivot connection between diverse morphologies of bladder carcinoma: a case report of urothelial carcinoma with villoglandular differentiation.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(3):3288-93. PubMed ID: 26045854
[TBL] [Abstract][Full Text] [Related]
9. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma.
Yang Y; Kaimakliotis HZ; Williamson SR; Koch MO; Huang K; Barboza MP; Zhang S; Wang M; Idrees MT; Grignon DJ; Eble JN; Baldridge LA; Cheng L
Urol Oncol; 2020 May; 38(5):449-458. PubMed ID: 31740332
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
11. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
[TBL] [Abstract][Full Text] [Related]
12. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of urine cytology in detecting histologic variants of urothelial carcinomas in the urinary bladder: Cytopathologic correlation of 72 cases.
Yoo Y; Choi E; Lee DH; Park S; Sung SH
Diagn Cytopathol; 2021 Mar; 49(3):367-373. PubMed ID: 33331144
[TBL] [Abstract][Full Text] [Related]
14. Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.
de Jong JJ; Valderrama BP; Perera J; Juanpere N; Cejas P; Long H; Albà MM; Gibb EA; Bellmunt J
Br J Cancer; 2022 Jul; 127(2):313-320. PubMed ID: 35449454
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
[TBL] [Abstract][Full Text] [Related]
16. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
17. The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer?
Linder BJ; Boorjian SA; Cheville JC; Sukov WR; Thapa P; Tarrell RF; Frank I
J Urol; 2013 Nov; 190(5):1692-6. PubMed ID: 23707452
[TBL] [Abstract][Full Text] [Related]
18. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
Bontoux C; Rialland T; Cussenot O; Compérat E
Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
[TBL] [Abstract][Full Text] [Related]
19. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital.
Shah RB; Montgomery JS; Montie JE; Kunju LP
Urol Oncol; 2013 Nov; 31(8):1650-5. PubMed ID: 22608543
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
Warrick JI; Sjödahl G; Kaag M; Raman JD; Merrill S; Shuman L; Chen G; Walter V; DeGraff DJ
Eur Urol; 2019 Jan; 75(1):18-22. PubMed ID: 30266310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
